Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide.
A large proportion of patients with HCC are diagnosed at advanced stages and are only …

Nonalcoholic fatty liver disease (NAFLD), including its more severe manifestation,
nonalcoholic steatohepatitis (NASH), has a global prevalence of 20–25% and is a major …

Background Immunotherapy with immune checkpoint inhibitors combined with an anti-
angiogenic tyrosine-kinase inhibitor (TKI) has been shown to improve overall survival versus …

Hepatocellular carcinoma (HCC) mortality rates are increasing globally, and particularly in
the Western world. Cirrhosis remains the predominant risk factor for HCC. However …

Background Systemic therapies have improved the management of hepatocellular
carcinoma, but there is still a need to further enhance overall survival in first-line advanced …

Single-agent immune checkpoint inhibitors (ICIs) have been tested in patients with
advanced hepatocellular carcinoma (HCC), leading to objective response rates of 15-20 …

Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide.
Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a …

Introduction The treatment landscape of hepatocellular carcinoma (HCC) has significantly
changed over the last 5 years with multiple options in the frontline, second line, and beyond …

Hepatocellular carcinoma (HCC) is the most frequent liver cancer with high lethality and low
five-year survival rates leading to a substantial worldwide burden for healthcare systems …

Regorafenib has anti-tumor activity in patients with unresectable hepatocellular carcinoma
(uHCC) with potential immunomodulatory effects, suggesting that its combination with …